Search Orphan Drug Designations and Approvals
-
Generic Name: | raloxifene | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trade Name: | Evista | ||||||||||||||||
Date Designated: | 07/14/2005 | ||||||||||||||||
Orphan Designation: | Reduction of the risk of breast cancer in postmenopausal women | ||||||||||||||||
Orphan Designation Status: | Designated/Approved | ||||||||||||||||
Sponsor: |
Eli Lilly and Company Lilly Corporate Center Drop Code 1853 Indianapolis, Indiana 46285 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
1 | Generic Name: | raloxifene |
---|---|---|
Trade Name: | Evista | |
Marketing Approval Date: | 09/13/2007 | |
Approved Labeled Indication: | Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer | |
Exclusivity End Date: | 09/13/2014 | |
Exclusivity Protected Indication* : | ||
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-